Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04406233
Other study ID # 31303720.7.0000.0068
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 23, 2020
Est. completion date May 23, 2022

Study information

Verified date May 2020
Source University of Sao Paulo
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The severe acute respiratory syndrome induced by the new coronavirus (SARS-CoV-2) has been declared a worldwide pandemic. Identifying common characteristics of the disease is crucial to promote a better prognosis for patients and to reduce the occurrence of medical complications, the time to medical discharge and mortality rates. Muscle mass and strength are recognized predictive measures of medical complications and mortality in different populations, but it is still unclear whether these also applies to patients with SARS-CoV-2. Therefore, this study will investigate whether muscle mass and/or muscle strength are predictors of the time until medical discharge of patients hospitalized with SARS-CoV-2. Our working hypothesis is that muscle mass and/or muscle strength are predictive measurements of the time until medical discharge of patients hospitalized with SARS-CoV-2


Description:

Muscle mass (via ultrasound) and muscle strength (via handgrip) of patients with SARS-CoV-2 will be assessed upon admission, medical discharge and 180 days after medical discharge. The time until medical discharge and any medical complications will be recorded. Throughout the hospitalization period, the mortality rate will also be assessed. One hundred and eighty days after medical discharge, the number of hospital readmissions, mortality rate and the use of public health services will be evaluated, to estimate the cost of each patient to the health service. Patients will be stratified according to muscle mass and strength assessed at admission. Data will be analysed using a mixed model with repeated measures assuming group (percentiles) and time (admission, medical discharge, and 180 days after medical discharge) for each dependent variable. In the event of a significant F-value, Tukey-Kramer post hoc adjustments will be used for multiple purposes. Survival rate will be examined using the Kaplan-Meier curve and analyzed using the Log-rank test (Mantel-Cox). The level of significance will be set apriori at P≤0.05.


Recruitment information / eligibility

Status Recruiting
Enrollment 176
Est. completion date May 23, 2022
Est. primary completion date May 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 Years and older ;

- hospital stay less than 48 hours;

- length of hospital stay to 48 hours no requiring invasive mechanical ventilation;

Exclusion Criteria:

- cancer in the last 5 years;

- delirium;

- cognitive deficit that impossibility the patient to read and sign the informed consent form;

- neurological disease;

- degenerative muscular disease.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Brazil Univsersity of Sao Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to medical discharge Length (in days) of the time hospitalization until medical discharge through the hospitalization period, an average of 15 days
Secondary All-cause mortality All-cause mortality rate along the study through the hospitalization period, an average of 15 days, 60, 180 and 360 days after medical discharge
Secondary Hospital readmission Occurrence of medical complications that require hospitalization 60, 180 and 360 days after medical discharge
See also
  Status Clinical Trial Phase
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Terminated NCT04435457 - Cardiovascular Implications of COVID-19
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A
Completed NCT04369794 - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Phase 4
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04542850 - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 N/A
Completed NCT04382040 - A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Phase 2
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT04378582 - Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
Completed NCT04383587 - Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers N/A
Recruiting NCT04402814 - IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
Completed NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2
Completed NCT04425889 - COVID-19 Antibodies Among Healthcare Workers
Completed NCT04395924 - Maternal-foetal Transmission of SARS-Cov-2
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers